HC Wainwright Forecasts Strong Price Appreciation for Immix Biopharma (NASDAQ:IMMX) Stock

Immix Biopharma (NASDAQ:IMMX) had its price objective increased by stock analysts at HC Wainwright from $12.00 to $15.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 84.05% from the company’s current price.

A number of other equities research analysts have also weighed in on IMMX. Mizuho began coverage on shares of Immix Biopharma in a report on Monday, February 9th. They set an “outperform” rating and a $14.00 target price on the stock. Citizens Jmp initiated coverage on Immix Biopharma in a report on Monday, March 9th. They set an “outperform” rating and a $23.00 target price on the stock. Wall Street Zen cut Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Finally, Morgan Stanley initiated coverage on shares of Immix Biopharma in a report on Wednesday. They set an “overweight” rating and a $20.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Immix Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Immix Biopharma Stock Performance

Shares of IMMX opened at $8.15 on Friday. Immix Biopharma has a 52 week low of $1.34 and a 52 week high of $11.61. The stock has a market capitalization of $431.71 million, a price-to-earnings ratio of -9.16 and a beta of 0.25. The stock has a fifty day moving average of $7.77 and a 200-day moving average of $5.26.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.12). As a group, equities analysts forecast that Immix Biopharma will post -0.87 EPS for the current year.

Hedge Funds Weigh In On Immix Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of IMMX. Allworth Financial LP acquired a new stake in shares of Immix Biopharma during the 4th quarter worth approximately $30,000. Mathes Company Inc. bought a new stake in Immix Biopharma in the fourth quarter valued at $56,000. Balyasny Asset Management L.P. bought a new stake in Immix Biopharma in the fourth quarter valued at $67,000. Kera Capital Partners Inc. acquired a new position in shares of Immix Biopharma during the fourth quarter valued at about $68,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Immix Biopharma during the fourth quarter valued at about $112,000. 11.26% of the stock is currently owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.